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With the spread of prostate specific antigen (PSA) examination， radical cure treatment by radica1 
prostatectomy has increased rapidly and the survival rate is high. However， about 26-68 % of disease 
of clinical stage cT1-2 are diagnosed as pT3 in postoperative pathology. Although the 5・yearPSA 
nonrecurrence rate is 91-97% for pT1-2， that for pT3 aNO and pT3 bNO is 76% and 37-40%， 
respectively. Appropriate adjuvant or salvage therapy for pT3 patient is necessary. However， at
present the standard treatment method has not yet been established. In this report， radiation and 
hormone therapy are evaluated as postoperative supporting treatments for pT3 and the appropriate 
treatment to be taken for pT3 is summarized. 
(Hinyokika Kiyo 51・571-573，2005)













































る.PSA 倍加時間 (PSADT)および Gleasonscore に
より 13例の salvage放射線療法の治療効果を検討した
ところ，ハイリスクとされる PSADT10カ月以下，ま
たは Gleasonscore 8以上を示した4例中 2例に再発
































































は，欧米における RCT(randomized controlled triaI) 




























試験 (RCT)の結果を待つとともに， PSA 倍加時間
(PSADT)など新たな基準を導入した治療方針が確立
されていくことを期待したい.
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